These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 33886457)

  • 1. Tocilizumab in Behçet's disease with refractory ocular and/or neurological involvement: response according to different clinical phenotypes.
    Atienza-Mateo B; Beltrán E; Hernández-Garfella M; Valls Pascual E; Martínez-Costa L; Atanes A; Moriano C; Cordero-Coma M; Nolla JM; Carrasco Cubero C; Sánchez Martín J; Calvo-Río V; Demetrio R; Palmou-Fontana N; González-Gay MÁ; Blanco R
    Clin Exp Rheumatol; 2021; 39 Suppl 132(5):37-42. PubMed ID: 33886457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet's disease: multicentre retrospective study.
    Atienza-Mateo B; Calvo-Río V; Beltrán E; Martínez-Costa L; Valls-Pascual E; Hernández-Garfella M; Atanes A; Cordero-Coma M; Miquel Nolla J; Carrasco-Cubero C; Loricera J; González-Vela MC; Vegas-Revenga N; Fernández-Díaz C; Demetrio-Pablo R; Domínguez-Casas LC; Luis Martín-Varillas J; Palmou-Fontana N; Hernández JL; González-Gay MÁ; Blanco R
    Rheumatology (Oxford); 2018 May; 57(5):856-864. PubMed ID: 29471416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet's disease. Multicenter study of 49 patients.
    Barroso-García N; Atienza-Mateo B; Ferraz-Amaro I; Prieto-Peña D; Beltrán E; Adán A; Hernández-Garfella M; Martínez-Costa L; Cordero-Coma M; Díaz-Llopis M; Herreras JM; Maíz-Alonso O; Torre-Salaberri I; De Vicente-Delmás A; Díaz-Valle D; Atanes-Sandoval A; Francisco F; Insua S; Sánchez J; Almodóvar-González R; Jiménez-Sosa A; Ruiz-Moreno O; Gandía-Martínez M; Nolla JM; Calvo-Río V; Castañeda S; González-Gay MA; Blanco R
    Semin Arthritis Rheum; 2023 Feb; 58():152153. PubMed ID: 36549244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
    Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
    Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of tocilizumab in Behcet's disease: A systematic literature review.
    Akiyama M; Kaneko Y; Takeuchi T
    Semin Arthritis Rheum; 2020 Aug; 50(4):797-804. PubMed ID: 32544751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients.
    Calvo-Río V; Santos-Gómez M; Calvo I; González-Fernández MI; López-Montesinos B; Mesquida M; Adán A; Hernández MV; Maíz O; Atanes A; Bravo B; Modesto C; Díaz-Cordovés G; Palmou-Fontana N; Loricera J; González-Vela MC; Demetrio-Pablo R; Hernández JL; González-Gay MA; Blanco R
    Arthritis Rheumatol; 2017 Mar; 69(3):668-675. PubMed ID: 27696756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apremilast in refractory orogenital ulcers and other manifestations of Behçet's disease. A national multicentre study of 51 cases in clinical practice.
    Atienza-Mateo B; Martín-Varillas JL; Graña J; Espinosa G; Moriano C; Pérez-Sandoval T; García-Armario MD; Castellví I; Román-Ivorra JA; Olivé A; Ybáñez A; Martinez-Ferrer A; Narváez J; Romero-Yuste S; Ojeda S; Ros I; Loricera J; Calvo-Río V; Castañeda S; Gonzalez-Gay MA; Blanco R;
    Clin Exp Rheumatol; 2020; 38 Suppl 127(5):69-75. PubMed ID: 33331268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of tocilizumab in Behçet's syndrome with refractory arterial lesions: a single-centre observational cohort study in China.
    Zhong H; Liu T; Liu Y; Zhang X; Zhou Y; Su Y
    Rheumatology (Oxford); 2022 Jul; 61(7):2923-2930. PubMed ID: 34791076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tocilizumab in Behçet Disease: A Multicenter Study of 30 Patients.
    Khitri MY; Bartoli A; Maalouf G; Deroux A; Salvarani C; Emmi G; Karadag O; Espinosa G; Leclercq M; Simonini G; Vautier M; Cacoub P; Saadoun D
    J Rheumatol; 2023 Jul; 50(7):916-923. PubMed ID: 36858435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Experience of Interferon Alfa-2a Treatment for Refractory Uveitis in Behçet's Disease.
    Park JY; Chung YR; Lee K; Song JH; Lee ES
    Yonsei Med J; 2015 Jul; 56(4):1158-62. PubMed ID: 26069144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review.
    Calvo-Río V; de la Hera D; Beltrán-Catalán E; Blanco R; Hernandez M; Martínez-Costa L; Loricera J; Cañal J; Ventosa J; Ortiz-Sanjuán F; Pina T; González-Vela MC; Rodríguez-Cundín P; González-Gay MA
    Clin Exp Rheumatol; 2014; 32(4 Suppl 84):S54-7. PubMed ID: 25005576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-label, prospective, single-arm study of switching from infliximab to cyclosporine for refractory uveitis in patients with Behçet's disease in long-term remission.
    Ida Y; Takeuchi M; Ishihara M; Shibuya E; Yamane T; Hasumi Y; Kawano S; Kimura I; Mizuki N
    Jpn J Ophthalmol; 2021 Nov; 65(6):843-848. PubMed ID: 34586526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab for treatment of severe Behçet's uveitis: a retrospective long-term follow-up study.
    Interlandi E; Leccese P; Olivieri I; Latanza L
    Clin Exp Rheumatol; 2014; 32(4 Suppl 84):S58-62. PubMed ID: 25005224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study.
    Santos-Gómez M; Calvo-Río V; Blanco R; Beltrán E; Mesquida M; Adán A; Cordero-Coma M; García-Aparicio ÁM; Valls Pascual E; Martínez-Costa L; Hernández MV; Hernandez Garfella M; González-Vela MC; Pina T; Palmou-Fontana N; Loricera J; Hernández JL; González-Gay MA
    Clin Exp Rheumatol; 2016; 34(6 Suppl 102):S34-S40. PubMed ID: 27054359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical profiling, treatment characteristics and outcome in Behcet's Disease (BD)-A retrospective cohort study from Karnataka Rheumatology Association (KRA).
    Rao VK; Kodali RS; Patil A; Chebbi P; Subramanian R; Kumar S; Singh YP; Chandrashekara S; Shobha V
    Clin Rheumatol; 2024 Oct; 43(10):3223-3230. PubMed ID: 39096360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease.
    Buggage RR; Levy-Clarke G; Sen HN; Ursea R; Srivastava SK; Suhler EB; Altemare C; Velez G; Ragheb J; Chan CC; Nussenblatt RB; Bamji AT; Sran P; Waldmann T; Thompson DJ
    Ocul Immunol Inflamm; 2007; 15(2):63-70. PubMed ID: 17558830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Characteristics of ocular involvement in Behçet disease in Tunisia: Monocentric study and review of literature].
    Ajili F; Bellakhal S; Ben Abdelhafidh N; Mrabet A; Zouari B; Maalej A; Louzir B; Laabidi J; Othmani S
    Pathol Biol (Paris); 2015 Apr; 63(2):85-90. PubMed ID: 25434793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tocilizumab in severe and refractory Behcet's disease: Four cases and literature review.
    Deroux A; Chiquet C; Bouillet L
    Semin Arthritis Rheum; 2016 Jun; 45(6):733-7. PubMed ID: 26743073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis.
    Tappeiner C; Mesquida M; Adán A; Anton J; Ramanan AV; Carreno E; Mackensen F; Kotaniemi K; de Boer JH; Bou R; de Vicuña CG; Heiligenhaus A
    J Rheumatol; 2016 Dec; 43(12):2183-2188. PubMed ID: 27633821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tocilizumab treatment for refractory uveitis-related cystoid macular edema.
    Adán A; Mesquida M; Llorenç V; Espinosa G; Molins B; Hernández MV; Pelegrín L
    Graefes Arch Clin Exp Ophthalmol; 2013 Nov; 251(11):2627-32. PubMed ID: 23893042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.